Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Profound Medical (PROF) EBITDA Margin (2024 - 2025)

Profound Medical has reported EBITDA Margin over the past 2 years, most recently at 117.61% for Q4 2025.

  • Quarterly results put EBITDA Margin at 117.61% for Q4 2025, up 2163.0% from a year ago — trailing twelve months through Dec 2025 was 250.27% (up 2929.0% YoY), and the annual figure for FY2025 was 250.26%, up 3662.0%.
  • EBITDA Margin for Q4 2025 was 117.61% at Profound Medical, up from 173.65% in the prior quarter.
  • Over the last five years, EBITDA Margin for PROF hit a ceiling of 117.61% in Q4 2025 and a floor of 655.33% in Q2 2025.